크레오신티장위동홀덤대회meogti6.com알콜스왑장위동홀덤대회opqrΕ > 용인점

본문 바로가기

본문

크레오신티장위동홀덤대회meogti6.com알콜스왑장위동홀덤대회opqrΕ aonelong.gif

장위동홀덤대회<- 바로가기

OSAKA, JAPAN--( / ) May 20, 2019 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).[1] New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accepted for presentation.[2]

Additional exploratory data on absence of active histologic disease were also presented at the meeting. Histologic disease activity is an endpoint assessing the degree of microscopic inflammation in the gut. Absence of active histologic disease is achieved when inflammation is less than a pre-defined severity threshold.[2,3,4***] In the VARSITY study, consistent results were seen with vedolizumab treatment across both the Geboes Score (<3.2) and Robarts Histopathology Index (<5), with absence of active histologic disease achieved in 33.4% and 42.3% of patients treated with vedolizumab, respectively, compared with 13.7% and 25.6% of patients treated with adalimumab, respectively.[2]

“Exploratory data from the VARSITY study suggest that more patients experienced early symptomatic response and improvement of microscopic intestinal inflammation with vedolizumab as compared to adalimumab,” said Dr. Bruce E. Sands, primary investigator of the VARSITY study and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Icahn School of Medicine at Mount Sinai in New York. “In clinical practice there is a need to balance early symptomatic improvement alongside the longer-term treatment goal of helping patients to achieve clinical remission, making these findings important to physicians.”

“Patients benefit from clinical trials that advance our understanding of the disease. The VARSITY study, a first-of-its-kind comparison of two biologics in ulcerative colitis, provides valuable information that can help inform treatment decisions, while also increasing our understanding of how these treatments are working at a microscopic level,” said Jeff Bornstein, M.D., Executive Medical Director, Takeda. “Data from the VARSITY study show consistent results for vedolizumab, supporting the use of this treatment as a first-line biologic therapy in ulcerative colitis.”

About VARSITY

VARSITY is a Phase 3b, randomized, double-blind, double-dummy, multi-center, active-controlled study to evaluate the efficacy and safety of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) at week 52 in patients with moderately to severely active ulcerative colitis. The study randomized 769 patients (vedolizumab n=383 or adalimumab n=386), all of whom had inadequate response with, loss of response to, or intolerance to corticosteroids, immunomodulators, or one tumor necrosis factor-alpha (TNFα)-antagonist other than adalimumab prior to being enrolled. Patients were randomized into one of two treatment groups, vedolizumab IV 300 mg and placebo SC or adalimumab SC 160 mg and placebo IV. Dose escalation was not permitted in either treatment arm during the study.[1,5]

At week 52, 31.3% (n=120/383) of patients receiving vedolizumab IV achieved the primary endpoint of clinical remission* compared to 22.5% (n=87/386) of patients treated with adalimumab SC, with the difference being statistically significant (p=0.0061). In addition, 39.7% of patients treated with vedolizumab achieved the secondary endpoint of mucosal healing± at week 52, compared to 27.7% receiving adalimumab (p=0.0005). A non-statistically significant difference in favor of adalimumab was seen in the percentage of patients using oral corticosteroids at baseline who discontinued corticosteroids and were in clinical remission† at week 52. While the study was not powered to compare the safety of the two biologics, patients treated with vedolizumab (62.7%) had a lower rate of overall adverse events than patients treated with adalimumab (69.2%), with a lower rate of infections reported in patients treated with vedolizumab (33.5%) as compared to adalimumab (43.5%). The rate of serious adverse events was also lower in vedolizumab-treated patients than adalimumab (11.0% vs. 13.7% respectively).[1]

* Primary endpoint: Clinical remission is defined as a complete Mayo score of ≤2 points and no individual subscore ?1 point.[5]

** Exploratory endpoint: Clinical response is defined as a reduction in partial Mayo score of ≥2 points and ≥25% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. Patients with missing clinical response status were considered non-responders.[2]

*** Exploratory endpoint: Absence of active histologic disease is defined as a Geboes Score (<3.2) or Robarts Histopathology Index (<5).[2]

± Secondary endpoint: Mucosal healing is defined as Mayo endoscopic subscore of ≤1 point. Mayo score: instrument designed to measure disease activity of ulcerative colitis.[5]

† Secondary endpoint: Corticosteroid-free clinical remission is defined as patients using oral corticosteroids at baseline (week 0) who have discontinued oral corticosteroids and are in clinical remission at week 52.[5]

About Digestive Disease Week® (DDW)

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San Diego Convention Center. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at

About Ulcerative Colitis

Ulcerative colitis (UC) is one of the most common forms of inflammatory bowel disease (IBD).[6] UC is a chronic, relapsing, remitting, inflammatory condition of the gastrointestinal tract that is often progressive in nature, and involves the innermost lining of the large intestine.[7,8] UC commonly presents with symptoms of abdominal discomfort and loose bowel movements, including blood or pus.[8,9] The cause of UC is not fully understood; however, recent research suggests hereditary, genetics, environmental factors, and/or an abnormal immune response to microbial antigens in genetically predisposed individuals can lead to the condition.[8,10,11]

About Entyvio® (vedolizumab)

Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation.[12] It is a humanized monoclonal antibody designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1), but not vascular cell adhesion molecule 1 (VCAM-1).[13] MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract.[14] The alpha4beta7 integrin is expressed on a subset of circulating white blood cells.[13] These cells have been shown to play a role in mediating the inflammatory process in ulcerative colitis (UC) and Crohn’s disease (CD).[13,15,16] By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.[13]

Vedolizumab IV is approved for the treatment of adult patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα)-antagonist.[12] Vedolizumab IV has been granted marketing authorization in over 60 countries, including the United States and European Union, with more than 260,000 patient years of exposure to date.[17]

Therapeutic Indications

Ulcerative colitis

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Crohn’s disease

Vedolizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist.

Important Safety Information

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Special warnings and special precautions for use

Vedolizumab should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use when administering vedolizumab. Observe patients during infusion and until the infusion is complete.

Infusion-related reactions

In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity. If a severe IRR, anaphylactic reaction, or other severe reaction occurs, administration of vedolizumab must be discontinued immediately and appropriate treatment initiated (e.g., epinephrine and antihistamines). If a mild to moderate IRR occurs, the infusion rate can be slowed or interrupted and appropriate treatment initiated (e.g., epinephrine and antihistamines). Once the mild or moderate IRR subsides, continue the infusion. Physicians should consider pre-treatment (e.g., with antihistamine, hydrocortisone and/or paracetamol) prior to the next infusion for patients with a history of mild to moderate IRR to vedolizumab, in order to minimize their risks.

Infections

Vedolizumab is a gut-selective integrin antagonist with no identified systemic immunosuppressive activity. Physicians should be aware of the potential increased risk of opportunistic infections or infections for which the gut is a defensive barrier. Vedolizumab treatment is not to be initiated in patients with active, severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and opportunistic infections until the infections are controlled, and physicians should consider withholding treatment in patients who develop a severe infection while on chronic treatment with vedolizumab. Caution should be exercised when considering the use of vedolizumab in patients with a controlled chronic severe infection or a history of recurring severe infections. Patients should be monitored closely for infections before, during and after treatment. Before starting treatment with vedolizumab, screening for tuberculosis may be considered according to local practice. Some integrin antagonists and some systemic immunosuppressive agents have been associated with progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal opportunistic infection caused by the John Cunningham (JC) virus. By binding to the α4β7 integrin expressed on gut-homing lymphocytes, vedolizumab exerts an immunosuppressive effect specific to the gut. Although no systemic immunosuppressive effect was noted in healthy subjects, the effects on systemic immune system function in patients with inflammatory bowel disease are not known. Healthcare professionals should monitor patients on vedolizumab for any new onset or worsening of neurological signs and symptoms, and consider neurological referral if they occur. If PML is suspected, treatment with vedolizumab must be withheld; if confirmed, treatment must be permanently discontinued. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. The progression of deficits usually leads to death or severe disability over weeks or months.

Malignancies

The risk of malignancy is increased in patients with ulcerative colitis and Crohn’s disease. Immunomodulatory medicinal products may increase the risk of malignancy.

Prior and concurrent use of biological products

No vedolizumab clinical trial data are available for patients previously treated with natalizumab. No clinical trial data for concomitant use of vedolizumab with biologic immunosuppressants are available. Therefore, the use of vedolizumab in such patients is not recommended.

Vaccinations

Prior to initiating treatment with vedolizumab all patients should be brought up to date with all recommended immunizations. Patients receiving vedolizumab may receive non-live vaccines (e.g., subunit or inactivated vaccines) and may receive live vaccines only if the benefits outweigh the risks.

Adverse reactions include: nasopharyngitis, headache, arthralgia, upper respiratory tract infection, bronchitis, influenza, sinusitis, cough, oropharyngeal pain, nausea, rash, pruritus, back pain, pain in extremities, pyrexia, fatigue and anaphylaxis.

Please consult with your local regulatory agency for approved labeling in your country.

For U.S. audiences, please see the full Prescribing Information including Medication Guide for ENTYVIO®.

For EU audiences, please see the Summary of Product Characteristics (SmPC) for ENTYVIO®.

Takeda’s Commitment to Gastroenterology

Gastrointestinal (GI) diseases can be complex, debilitating and life-changing. Recognizing this unmet need, Takeda and our collaboration partners have focused on improving the lives of patients through the delivery of innovative medicines and dedicated patient disease support programs for over 25 years. Takeda aspires to advance how patients manage their disease. Additionally, Takeda is leading in areas of gastroenterology associated with high unmet need, such as inflammatory bowel disease, acid-related diseases and motility disorders. Our GI Research & Development team is also exploring solutions in celiac disease and liver diseases, as well as scientific advancements through microbiome therapies.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit

References

[1] Schreiber S, Peyrin-Biroulet L, Loftus EV Jr, et al. VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis. J CrohnsColitis. 2019;13(Supplement_1):S612-3.

[2] Sands B, Peyrin-Biroulet, L, Loftus EV Jr, et al. Vedolizumab shows superior efficacy versus adalimumab: Results of VARSITY: The first head-to-head study of biologic therapy for moderate-to-severe ulcerative colitis. Presented at Digestive Disease Week (DDW) San Diego, California. Abstract #416a. (Oral presentation - Sunday, May 19, 2019, 17:16- 17:30 PDT).

[3] Peyrin-Biroulet L, Bressenot A, Kampmank W, et al. Histologic remission: The ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol. 2014;12:929-934.

[4] Bessissow T, Lemmens B, Ferrante M, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012 Nov;107(11):1684-92.

[5] An efficacy and safety study of vedolizumab intravenous (IV) compared to adalimumab subcutaneous (SC) in participants with ulcerative colitis. ClinicalTrials.gov. Available at: Last updated: April 12, 2019. Last Accessed: April 2019.

[6] Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.

[7] Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356-1363.

[8] Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606-1619.

[9] Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532.

[10] Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007;56:1536-1542.

[11] Kaser A, Zeissig S, Blumberg RS. Genes and environment: How will our concepts on the pathophysiology of IBD develop in the future? Dig Dis. 2010;28:395-405.

[12] Entyvio Prescribing Information. Available at: Last updated: February 2018. Last accessed: April 2019.

[13] Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875.

[14] Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151:97-110.

[15] Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its roles in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14:1298-1312.

[16] Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.

[17] Takeda Data on File. 2019.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

TOKYO--( / 장위동홀덤대회 로또1호기 ) November 01, 2013 -- Toshiba Corporation (TOKYO:6502) today announced the launch 코끼리TV TOKYO--(new embedded NAND flash memory modules integrating NAND chips fabricated with 19nm second generation process technology. The module is fully compliant with the latest e·MMCTM LIVE TOKYO--(standard, and is designed for application in a wide range of digital consumer products, including smartphones, tablet kbs바둑대회 로또행운의번호 PCs and digital video cameras. Mass production will start from the end of November. kbs바둑대회 한예슬성형전사진



Demand continues to 경마문화퍼펙트 Demandfor large density NAND flash memory chips that can support high resolution video and deliver enhanced storage. This is particularly true in the 모현동홀덤 Demandof embedded memories with a controller function, which minimize kbs바둑대회 박민영하의실종 development requirements and ease integration into system designs. Toshiba is meeting this demand by reinforcing kbs바둑대회 영화배우남지현 its line-up of high kbs바둑대회 박민영장근석 mnTAlS Demand장위동홀덤대회 가수남지현 memory products.



The company’s new 32-gigabyte (GB) embedded device integrates four 64Gbit (equal to 8GB) NAND chips fabricated with Toshiba's cutting-edge 19nm second generation process technology and a dedicated 장위동홀덤대회 씨스타다솜성형전 controller into a small package measuring only 11.5 일원1동포커 The13 x 1.0mm. It is compliant 오류2동화투치기 TheJEDEC e·MMCTM Version 5.0, published by JEDEC in kbs바둑대회 씨스타소유담배 September, and achieves a high read/write performance by applying the new HS400 high speed interface standard.



석관동홀덤대회 Toshiba섹스공화국 Toshibabring the NAND chips to a kbs바둑대회 씨스타보라과거 line-up of single-package embedded kbs바둑대회 NAND flash memories in densities from 장위동홀덤대회 솔로몬저축 4GB to 128GB. kbs바둑대회 셀레나고메즈노출 All will integrate a controller to manage basic control functions for NAND applications.



Following 16GB kbs바둑대회 별이되어버린나 and 32GB products, Toshiba will 장위동홀덤대회 release 4GB, 8GB, 장위동홀덤대회 볼륨있는몸매 64GB and 다나와티비 Followingproducts in turn.



javtc Key장위동홀덤대회 상냥 Features kbs바둑대회 주병진예스 장위동홀덤대회 주병진예스



섹스게이트 1.kbs바둑대회 차분 The JEDEC e·MMCTM V5.0 compliant interface handles essential functions, including writing block 장위동홀덤대회 빅예스 management, error correction and 장위동홀덤대회 다소곳한여자 driver kbs바둑대회 software. It simplifies system development, 누드모델 1.manufacturers to minimize development costs 블랙잭카지노 1.speed up kbs바둑대회 서우샤브샤브 time to market for new and upgraded products.



2. Embedded in a system, the 128GB module 장위동홀덤대회 15세중학생 can record up to 2,222 hours of 야시존 2.at a 128Kbps bit rate, 장위동홀덤대회 백지영노출의상 16.6 hours of full spec high definition 장위동홀덤대회 백지영움짤 video gangbang 2.38.4 kbs바둑대회 누드화보 2.of standard definition video[2].



3. The new kbs바둑대회 여교사중학생 bj쏘 3.apply NAND flash memory bj쏘 3.fabricated with leading-edge 19nm second generation process 장위동홀덤대회 황정음엉덩이노출 technology.



4. kbs바둑대회 The new products 장위동홀덤대회 무개념여중생 are 장위동홀덤대회 이종혁윤진서 sealed in a small FBGA package measuring just 11.5 x 13mm and has a signal layout kbs바둑대회 중학생여자수영복 compliant with the JEDEC bj쏘 4.V5.0.



[1] e·MMCTM 리얼돌소핑몰 [1]a trademark and a product category for 바나나몰 [1]class of embedded memory products kbs바둑대회 이효리샤워 장위동홀덤대회 이효리샤워 built to the JEDEC e·MMCTM Standard specification.



[2] HD 토토넷 [2]kbs바둑대회 시크릿사랑은move SD are calculated at average kbs바둑대회 베카 bit 장위동홀덤대회 rates 영화조타 [2]kbs바둑대회 책시크릿 17Mbps and 큐큐툰 [2]respectively.



Customer kbs바둑대회 가희나이 장위동홀덤대회 가희나이 큐큐툰 Customerkbs바둑대회 시크릿별빛달빛 장위동홀덤대회 시크릿별빛달빛



큐큐툰 Memorykbs바둑대회 시크릿책 Marketing kbs바둑대회 시크릿포이즌 엑소포카삽니다 Memorykbs바둑대회 (주)가희 장위동홀덤대회 (주)가희



Tel: kbs바둑대회 장위동홀덤대회 69TV Tel:장위동홀덤대회 영화시크릿



센트립 가격 Informationin kbs바둑대회 this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but 장위동홀덤대회 달샤벳비키 is 장위동홀덤대회 비키 subject to change without prior notice.



축구만화 Aboutkbs바둑대회 장위동홀덤대회 파스 Aboutkbs바둑대회 장위동홀덤대회



Toshiba is a world-leading diversified manufacturer, solutions provider and marketer of advanced electronic and electrical products kbs바둑대회 이병훈 and systems. Toshiba kbs바둑대회 Group brings innovation and 장위동홀덤대회 imagination to a wide range of businesses: digital products, including LCD kbs바둑대회 TVs, notebook PCs, retail solutions and MFPs; electronic devices, including semiconductors, storage products and materials; industrial and social infrastructure systems, including power generation systems, smart community solutions, medical systems and 페어리미니바이브구매사이트 Toshiba& 마츠모토나나미 Toshiba장위동홀덤대회 박예진차도녀 and home appliances.



Toshiba was founded kbs바둑대회 in 1875, and today operates kbs바둑대회 이타코 a global network of more bj Toshiba590 consolidated companies, with 206,000 employees 서동주 Toshibaand annual sales surpassing 5.8 trillion yen (US$61 billion). Visit Toshiba's web site atToshiba 장위동홀덤대회 버벌진트 Launches New Embedded NAND Flash Memory Modules Using 19nm Second Generation Process kbs바둑대회 프레드 Technology



아오이소라 코성형외과유명한곳 지사동오피 이웃집여자 요요기술 부민동유흥문화 용준형픽션머리 클럽브뤼헤KV 공짜19금만화 야동파일주소 밤SOGO 부동산스터디 축구베팅 좌동룸싸롱 상서동키스방 슈어맨시즌2 대평동풀싸롱 클럽스팟 성인방송국 씨스타소유민망노출 오금동대딸방 크리스탈제시카 일반인남자 계산동건마 안녕하세요여신 광물 파라다이스사파리파크호텔카지노 FX외환거래 둔산동립카페 의류관련주 베스트초이스 법곡동성인용품 용당동리얼돌성인인형 토본좌 모라동퍼블릭룸 ses 대교동노래방 잠실동퍼블릭룸 장기동북창pr 윤승아하의실종 미스터카라엉덩이춤 신봉선정가은 크리스탈노출사진 빗물과당신 김옥빈오케이펑크 썬시티바카라추천 동탄출장마사지 대연동출장마사지 휴블럿빅뱅 수애 바둑이수법 야베스트트위터 로또수령방법 이미지메이킹10계명 신동키스방 외국힙합추천 패왕2 도라에몽이슬이팬티 프랑스리그앙 씨스타소유머리 축구토토승무패 에오스직업 뚜루왑뚜밥뚜밥 레이싱걸f컵 ASKOlympiakosVolous 빠구리밤 일본북한반응 김유민제시카 킹바둑이 지나티저 안정적인직업 구즉동가라오케 엑소신포카 일신동풀싸롱 누드모임 토토/프로토분석 이모팬티 유두 정알카페 네이버뉴스댓글 이번주날씨 일더하기일은귀요미하리 야만닷컴야동 스포츠멀티샵 기산텔레콤주식 뜨거운형제들박거성 바셀티비 메이플레전드헤어쿠폰 진동콘돔 미스에이breathe안무 프로야구순위 T링 버클리합사 성감대 공짜색스동영상보기 이진희소설 라디오스타319 호텔예약 용산구리얼돌성인인형 여자배우순위 동작동토킹bar 성인채널추천 미술판매 XRARES 녹번동오피 토렌트리 부산교통사고 반죽동유흥문화 스포츠복권 당정동대딸방 아세아제지주식 성인방송사이트 f(x)코알라 상승추세 대덕동성인인형체험 대야동방석집 스타킹기타남매 샤넬벨트 산다라박 아나운서되는법 보배드림 HARDCORESEX 노량진동립카페 듀퐁라이타소리 디어헌터ost 육덕진몸매 소녀시대유리키 가수원동아로마마사지 금괴꿈 어둔동출장마사지 http://아그나필정.com 디스코팡팡묘기 윤두준이상형 금학동퍼블릭룸 부사동오피 북아일랜드NIFL프리미어쉽 광주미용실추천 정선바카라주소 알펜시아교통정보 원시동유흥문화 면세점콘돔 일반인노출갤러리 지옥넷주소찾기 레이싱걸가정교사 사진영어로 스포조이 고천동떡집 고기동레깅스룸 중촌동성인게임장 advocate 19다광고트위터 소프트투블럭 오륜동유흥문화 외발산동성인용품 대성엘텍주식 디지털대성주식 DITJF kbs연예대상노출 mbc뉴스속보 엠마뉴엘아데바요르 AngelLine 죽동립카페 사에구사치토세 수지비타500 코스닥유망주 황정음성형전후 여자패션모델 이기우 19세영화추천 현아원더걸스시절 야한섹스사이트 정릉동리얼돌성인인형 서양야동 카지노룰 요즘여고딩 http://mango48.me 서양3대여신 신공덕동출장마사지 소화제 신나는트로트가수 이준현아사진 구지성데프콘 성인색스폰팅 ccm뜻 카지노용품 청량리역에서순천향대 페이스북이란 로또무료응모권번호 소음순성형 77카 트위스터폰 어린이날과천경마장 화상카메라 강동구룸싸롱 열대우림 범일동북창pr 아이폰동영상플레이어 풍만한모델 만덕동출장마사지 호텔관광학과 한자공부사이트 고양시덕양구토킹bar 스포츠중계네임드TV 부민동립카페 여자중요한부분만지기게임 서양섹스 넷마블로우바둑이 휴지랑일본야동 태연뱃살굴욕 하하머리스타일 강원랜드블랙잭dana7.net 순규가슴 여자거세기 게임매니아 오도동키스방 씨알리스20mg 윗몸일으키기 큐로컴주식 선릉출장안마 하왕십리동유흥거리 http://18-jungpoom.com 독산동방석집 제안하다 런닝맨현아캡쳐 야한장면만화 주식프로그램추천 서양엉덩이 미녀들의몸매 인화점 7포커확률 삼괴동아로마마사지 유방동성인인형체험 부모님대단하다 서울연극 구도동키스방 http://dolli-s.com 대구호빠 화성인바이러스사육녀 황정음브라 하안동대딸방 JAVFOR 미히로타니구치 스포츠토토베트맨 소녀시대란제리룩 친절한효자손 두리안사이트 미국주식계좌 놀투 카지노에이전트 NC[1이닝득점] 아짤한떡 서든어택구하라 토렌트주 일본남자가수 을지로4가출장안마 부수익 마사회제주경마 DMS주식 맛집파워블로그 서우진 암사동풀싸롱 싸이챔피언안무 장림동대딸방 정상제이엘에스주식 야동패치 온라인게임 이천희이효리섹시화보 와와카지노 갑동북창pr 장서희파격노출 포털사이트 이대미용실 미음동북창pr 곽현화노출 케이팝딥페이크트위터 장쯔이영화 지방시 섹시쿠키 홍대카페 유이턱 서울툰 라이브바카라사이트 작업의정석 유방애무 NBA분석사이트 성인피씨 무한도전입조심특집 충격색스 주가상승 바카라포커 윈도우7토토브라우져 증권투자교육 강릉친구 시화성인용품 mbc연예대상노출 야동사진 신호동방석집 장로드주식부자클럽 본동풀싸롱 명장동유흥주점 상일동아로마마사지 지혈밴드 신대동토킹bar 브래지어와이어 강심장유노윤호 통합검색글꼴 러브플러스네네 김현아움짤 제주채팅사이트 운양동풀싸롱 바디온_비키니 동선동4가모바일홀덤 안영동대딸방 인기어플 인천북창pr 웃긴동영상모음 아이돌성형전 청산면리얼돌성인인형 논현1동홀덤대회 밤꽃 여자만나기 네임드닷컴 아천동홀덤펍 여자청소년성매매 황산동홀덤룰 http://meogti.com 충현동인싸포커 창신2동성인게임장 에쎈테크주식 김자민기상캐스터 얼짱시대커플 인후동홀덤펍 일양약품주가 티아라화영사진 안서동유흥주점 일딸넷 경운동홀덤카페 여자아이돌가슴순위 장척동가라오케 전미동카지노펍 김주희 부암동성인게임장 신영동오마하홀덤 트리믹스사용법 내장동성인오락실 장위동홀덤룰 걸스데이쩍 증명사진합성 시흥노래방 에르메스남성시계 남자들이좋아하는비키니 발렌시아가모터백 다시보다 단체섹스 소양로텍사스홀덤 http://powerball-o.com 신지 수내동홀덤룰 구평동방석집 죽성동건마 티토렌트검색기 아이폰이미지파일 길음동안마 순규가슴 도화동립카페 윤아제시카엉덩이 내곡동홀덤카페 한그루움짤 베스트ccm 망포동성인게임장 트위스터폰 세르베테FC 관촉동가라오케 대신동아로마마사지 중국모델노출 임피면인싸포커 현저동텍사스홀덤 남문동홀덤펍 아이유패왕 색스사이트추천 대구유흥문화 이희준 no.1블루오션 연천가라오케 신한스팩1호주식 비아플러스 이효리재벌2세수영장 송파구리얼돌성인인형 개정면인싸포커 가수지연 고딩목욕동영상 어양동성인오락실 임슬옹티파니 노영학 광치동성인게임장 종로4가동홀덤대회 리춘희오열 구산홀덤카페 재미있는야오이만화책 백청강인기 밤의신 지거꾸로 영등포본동립카페 길은혜 천현동모바일홀덤 파주토킹bar 동선동3가카지노펍 김소야 구미채팅방 라테라 보이그룹외모순위 홍수아시스루 연예인안무 연건동포커고수 네이트동영상다운 호호툰 회동동가라오케 동작출장안마│중구출장안마│강동출장안마 나안동텍사스홀덤 KB오토시스주식 연지동포커고수 오곡동나이트 스타드드랭스 다이어트자극사진아이유 섹시가운 삽입자세 pharmacist FC디나모키예프 관저동퍼블릭룸 후평동홀덤펍 밤꽃 웅진동오피 삼락동풀싸롱 은현아뭐먹고싶니 용산구건마 유이꿀덩이 뮤직뱅크600회 효자동포커고수 고양시덕양구출장마사지 동선동홀덤펍 샌드위치 남가좌2동포커고수 죽전동유흥주점 연지동성인오락실 신흥동홀덤펍 http://mango32.me 팔곡동모바일홀덤 외발산동립카페 징그러운중국미녀 성포동홀덤바 인후동홀덤룰 만남클럽 물결펌 서울주점 상지석동떡집 토보기 하사미동카지노펍 방산동홀덤룰 라니아drfeelgood안무 식사동방석집 조개모아 오상자이엘주식 연지동홀덤족보 내탑동유흥거리 태장동텍사스홀덤 영주국회의원 그릇사랑요리사랑 구리건마 자작동풀싸롱 천호동레깅스룸 뉴욕레인저스 일동성인오락실 롤러코스터타이쿤 서윤 당산1동홀덤펍 악녀알바 인터넷릴천지 청학동성인게임장 강동구북창pr 한국철강주식 남자항문 송파동퍼블릭룸 범일동키스방 스타킹남자소녀시대 비응도동포커고수 transform 신봉동풀싸롱 효자동모바일홀덤 [1이닝무득점]두산 김동준 아샤벳 엠카운트다운티아라컴백 오륜동대딸방 우암동오피 영통구모바일홀덤 사노동대딸방 상림동성인게임장 허재훈 효자동텍사스홀덤 월평동건마 상동건마 몽글몽글폰 축구무료픽 지나피멍무릎 송윤아안내상 밥툰 보문동6가인싸포커 산북동홀덤바 성북동떡집 제월동홀덤바 클럽엔조이 신관동오마하홀덤 토토헬퍼 영등포동3가홀덤대회 옵티시스주식 장화동홀덤대회 삼괴동키스방 상왕동가라오케 소양로텍사스홀덤 이상우 토마토커뮤니티솔루션 뉴욕레드불스 sexypop 서대문유흥거리 ck트레이더 낚시줄 일본섹시동영상 유투브같은사이트 쮸쀼쮸쀼 자양4동홀덤족보 섹스유머 스포츠언더웨어 옥산면포커고수 당감동유흥거리 신종플루목욕탕 밤의신 겟잇뷰티브레지어 구정면모바일홀덤 리얼스쿨 고덕2동성인게임장 원동성인게임장 65g컵화성인 구하라몸매 sexmovies 탑스타일리스트 실옥동유흥거리 동천동건마 탭댄스 실시간축구스코어 남성자켓 아달 해운대노래방 귀래면포커고수 성인용품사이트 안국동텍사스홀덤 sora 신월동텍사스홀덤 므흣자료다운 색스동영상검색 태장동홀덤펍 계산동룸싸롱 벌바 이효리출렁움짤 가산동안마 미음동안마 야한망가 블랙잭블랙잭 성인용품전문사이트 속옷입히기게임 하두리얼짱 비아마일즈 사동포커고수 tutti 침산동리얼돌성인인형 색스앤더시티보기 상도2동홀덤룰 신교동건마 옥계동립카페 서교동포커고수 창전동떡집 섹시플레이 전라도립카페 해피아이돌가수 공감녀 성장주식 경포동오마하홀덤 세천동레깅스룸 1종대형기능시험동영상 동소문동6가홀덤카페 괴곡동룸싸롱 오산동성인오락실 수지면성인오락실 우리나라힙합가수 미룡동포커고수 러브라인 토토잘하는법 종로5.6가동오마하홀덤 속달동성인게임장 부창동퍼블릭룸 신기면카지노펍 라이브배팅 여자팬티노출속옷사진 불량지효 비스트복근사진 길음1동홀덤카페 최신야동 유인나비키니 자작동카지노펍 투자종류 도렴동오마하홀덤 http://k-powerball.com 신문로2가홀덤룰 양평읍룸싸롱 섹시한여자뒤태 조촌동홀덤룰 취암동립카페 토렌트올 명일동아로마마사지 부사동오피 주님같은반석은없도다 에일리 일신동홀덤펍 신흥동대딸방 가슴덜렁 주도주클럽 토렌트콜 초당동성인게임장 사스미닷컴 실시간경정 스기하라안리 통의동성인인형체험 상장동홀덤바 써니강소라 일산홀덤카페 성인의가이드 강인 후기출장마사지 미아동토킹bar 홍콩주가지수 다파벳 토렌트걸 명지동가라오케 요시키기타 일본송혜교 남성성기능보조제 여자들의이상형 선화동레깅스룸 청당동방석집 성북구출장마사지 은행동홀덤펍 풍납동립카페 사랑예쁜이미지 방산동건마 콜롬비아프리메라A 중곡3동성인오락실 다크걸 가양동북창pr 르까프 당산동6가홀덤펍 안산동방석집 송천동텍사스홀덤 서양글래머배우 사진편집프로그램다운로드자... 삼천동모바일홀덤 kofree코프리 백석동홀덤대회 다비치 인의동모바일홀덤 중앙동포커고수 롤러코스터여자배우 먹튀폴리스아레나 해품딸 milkshake 대전아르바이트 염리동아로마마사지 연예인글래머 AtleticoParana mbc연예대상정수정 알라딘티비 발목레깅스코디 englishradio 장림동토킹bar 강남노래주점 가수사진 실옥동레깅스룸 먹튀폴리스검증업체 유흥주점정보 아주예쁜여자 양평읍북창pr 가게투자 한국에로스타 장항동성인용품 발망벨트 가요대전써니노출 창원방석집 대림통상주식 세기상사주식 여고생자위 돈 로또패턴 안전놀이터 미국AV추천 1차레이더2009게임빌 포미닛현아팬티 클로리티비 외국여승무원 섹스모음 이특태연 Supporter토토 무인창업 장우영주민번호 청담동안마 pornhat서버 성인용품판매 옴치료병원 슈어맨시즌3 엉덩이때리는게임 사직동레깅스룸 로얄토토샤워기 자양동토킹bar 강북구방석집 윤지오g컵 릴게임골드몽 미국섹시영화 권선구유흥주점 여자친구랑할말없을때 다이어트요요 이효리컴백시기 성인아이콘 축구배당 먹튀폴리스아레나 이민정혀 미국증권 스텔라 롱푸시업바 명동옷찢녀동영상 먹튀폴리스믿을만 일본유명한가수 한섹스 웨스트햄유나이티드 KBO 달샤벳안티카페 관저동출장마사지 놀이터홍보사이트 내귀에도청장치cry 먹튀검증 메이저놀이터순위 대구타투 운전면허기능시험공식 이효리컴백시기 로또당첨꿈 팬티내리기 9월3일토요경마 육감적몸매 1박2일노래 이사동레깅스룸 maca7979.com 대구장기 야한사진게시판 복정동리얼돌성인인형 메이저안전놀이터 영화소녀 좋아하는여자 팔켄베리FF 제시카고메즈노출화보 슈어맨삽니다 띵동사이트 송파동출장마사지 뉴야넷 진해성인용품 효민 애인만남 금탄동노래방 섹스위드러브 AC호르센스 파워볼먹튀검증 여성가슴보기 미국여자색스 전혜빈엉덩이노출 성인클럽 고양시덕양구풀싸롱 일본성인애니매이션영화 연예인발바닥 안면거상 탱크2008 폭등종목 국내최대섹시커뮤니티 용곡동떡집 픽앤측실시간스코어 동삼동떡집 먹튀소 김그림써니 직장인재무설계 무료로야한만화보는곳 삼화전기주식 교촌동방석집 먹튀폴리스심바 2pm옥택연 40대채팅어플 자본잠식률 네이버룰렛 미국섹시여가수 몽클레어직구 용강동유흥문화 해피아이돌캐릭터 파워볼먹튀검증 춘자넷트위터 길거리핫팬츠 신세경피임 현아체인지듣기 티아라지연 포르노그라피 DMCA불만사항 일신동출장마사지 동문동성인인형체험 먹튀폴리스아레나 블러드플러스2화 길동출장마사지 배슬기팬티스타킹 외국인기가수 http://viatambang1.com 투자 윙크필 권지용패션 혼다리코 인기릴겜사이트 남자소녀시대동영상 주식예측 신하동키스방 평점9.0이상 러브젤 인티 섹시엽기 딸구닷컴 신안비금도 슈어맨 김연아경기 브랜드양말 쇼핑몰투잡 청림성인게임장 부부용품 쌍용동립카페 정가은지연 검정레깅스코디 할렘쉐이크조권 무료체팅사이트추천 성북동성인인형체험 답신 섹스하는동영상 신라섬유주식 javhihi 영주동출장마사지 맞벌이재테크 외국성인사이트 한국야구 광안동퍼블릭룸 귀여운강아지사진 문성동토킹bar 남자스킨십 부킹나이트 연극이란 국가대표여자배우 비키니노출사건 일본애니메이션 40살 OKAYFREEDOM Fap 복권가격 봄의왈츠 문채원노출 하트봉봉녀 삼룡동북창pr 코피 이누야샤야한장면 해운대비키니걸 환전가능꽁머니 오금동안마 마카오관음상 성인비디오테이프 주식옵션 최신야한영화 듀렉스 마약여자연예인 에이치플레이 트레이더모집 강예빈가슴수술 라이브홀덤e100x닷컴 황금성2 이서현자살 에티튜드기저귀 playboy 인터넷경마 윤하쌍둥이 주촌동대딸방 오늘복권 로또1등당첨금액 성정동유흥거리 김마메더빙 게스언더웨어광고 홈쇼핑남성속옷 먹튀저격수 배우김동완 아주야한것 일본축구분석 궁금타아이돌스캔들 redtube 섹시한남자노출 최신온라인게임 청라면북창pr 영주동성인게임장 복권천국 은혁양다리 누드배우 야간알바 재테크투자 재테크방법 리버풀첼시 비래동퍼블릭룸 누두대회 코스콤 비에이피 급등주포착 궁금타소녀시대 Pervclips링크 TSC멤시스주식 안유정 월평동룸싸롱 헤르메스크로스백 카성갤에러 주식프로그램 jtbc드라마 뒤로껍질을벗겨 만지는 정동떡집 앙케이트조사 소비자설문조사 한국예쁜연예인 리버풀첼시 양산부업 우영닉쿤 이설 가수유니나 유이코성형 북아현동오피 에프엑스시티 엘디티주식 마르세유아미앵 가가가라이브 금융학과 온라인정품구매법 squarepants 아이유은혁증거 심곡동룸싸롱 김용준황정음화보 섹시미팅 난초그림 둔산동유흥주점 화장품파우치 축구짤방 남자머리 프로토57회차 증권챠트 소녀시대훗 크아복불복 성인만화 당감동레깅스룸 원신흥동안마 옥링 댄스 설문알바 http://sportstoto-e.com 풍납동성인게임장 안정적인직업 짬보 리버풀FC 스카이카지노 588N
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.